Human trial
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Healthy adults aged 21-61, 28/49-day experiments
Reported findings. Increased GH and IGF-I
Nonresponse. No recovery/body-composition outcome established
Harms. No serious reactions reported during short study; not long-term safety
Limits. No transfer to other routes/formulations/indications; clinician review pending.
Preparation: Long-acting CJC-1295 with DAC, not no-DAC Route: subcutaneous
Read original source ↗Editorial review 2026-10-09. Clinician review pending.